Substituted 16,17-annellated steroid compounds for use in women's healthcare
OA: closed
AI-generated summary
This invention describes substituted 16,17-annellated steroid compounds designed for the treatment and prevention of endometriosis, as well as contraception, hormonal therapy, osteoporosis management, and uterine fibroid care.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
The present invention relates to substituted steroid compounds having the formula (I) Wherein R is H or halogen R is H, (1C-4C)alkyl, (1C-4C)acyl, glucuronyl or sulfamoyl R is H or halogen R is H, (1C-4C)alkyl, (2C-4C)alkenyl or (2C-4C)alkynyl R is methyl or ethyl R is H or methyl R is H or methyl R is H or acyl for use in the treatment and prevention of endometriosis, for contraception, for hormonal therapy in perimenopausal and post-menopausal women, for the treatment of osteoporosis and for the treatment uterine fibroids and other menstrual-related disorders, such as dysfunctional uterine bleeding.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-08-06T06:07:45.168820+00:00